Memantine Cristers

Memantine, the active ingredient in Memantine Cristers, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adults, helping to improve cognition and daily functioning.

GNH USA supplies Memantine Cristers as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Memantine acts on the glutamatergic pathway and is used primarily in the management of Alzheimer’s disease, where excessive NMDA receptor activation contributes to neuronal injury.

Alzheimer’s disease: improves cognition, memory, and functional abilities in patients with moderate to severe disease.

Memantine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue - Confusion - Hypertension

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmias - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hepatic dysfunction - Suicidal thoughts or behavior - Severe rash or hypersensitivity reactions

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential complications. - Renal function: adjust dose in moderate to severe impairment. - History of seizures: monitor closely for increased seizure risk. - Cardiovascular disease: assess blood pressure and heart rhythm regularly. - Hepatic impairment: use with caution and monitor liver enzymes. - Concomitant NMDA antagonists: avoid combined use to prevent additive toxicity. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive CNS depression and cognitive impairment. - Dextromethorphan: heightened risk of dizziness and confusion.

Moderate Interactions (Monitor Closely): - Acetylcholinesterase inhibitors (e.g., donepezil): monitor for additive cognitive effects. - CNS depressants (e.g., benzodiazepines): observe for enhanced sedation. - Drugs affecting renal clearance (e.g., cimetidine, NSAIDs): adjust memantine dose if needed.